esomeprazole+bismuth+tetra+levo

PreclinicalSmall molecule

esomeprazole+bismuth+tetra+levo is one of 6 small molecule programs targeting H Pylori Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

H Pylori InfectionCompleted

H Pylori InfectionPreclinical

Completed

Competition

Competitive Landscape

8 competitors in H Pylori Infection

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

5 2

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

6 3

Levaquin

WWim Janssens

Approved

3 4

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

2 5

Takecab

PPhathom Pharmaceuticals, Inc.

Approved

1 6

esomeprazole+bismuth+tetra+levo

KKaohsiung Veterans General Hospital.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

H Pylori Infection1 trial

Levofloxacin Triple and Bismuth Quadruple Therapies for Rescue Treatment of H Pylori Infection

Completed·KKaohsiung Veterans General Hospital.·N/A·NCT02978157·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for esomeprazole+bismuth+tetra+levo. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — esomeprazole+bismuth+tetra+levo compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for esomeprazole+bismuth+tetra+levo. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kaohsiung Veterans General Hospital. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKaohsiung Veterans General Hospital.

esomeprazole+bismuth+tetra+levo

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

H Pylori Infection1 trial

References

Drug Info

Quick Facts

Related News